Breastcancer.org Podcasts: Listen to Experts Discuss
Comments
-
Where Are We With Immunotherapy for Breast Cancer? ESMO 2019 Coverage
September 27, 2019
Dr.
Jennifer Litton is a board certified medical oncologist and professor
of breast medical oncology at the University of Texas MD Anderson Cancer
Center in Houston, where she is chief of the Section of Clinical
Research and Drug Development for Breast Cancer. She also is a member of
the Breast Immuno-Oncology Task Force of the National Cancer Institute.
At the European Society for Medical Oncology 2019 Congress, she
presented information on a study she's leading, looking at combining a
new type of immunotherapy with a traditional chemotherapy medicine. She
joined us to talk about current immunotherapy research for breast cancer
in general as well as what is specifically being presented at the
congress.Listen to the podcast to hear Dr. Litton discuss:
- why
immunotherapy medicines to treat breast cancer will likely be used with
another type of therapy, such as chemotherapy or radiation therapy - the difference between a "hot" and "cold" tumor and why that is important for immunotherapy
- other biomarkers besides PD-L1 that may help doctors decided if an immunotherapy medicine will work
Running time: 16:50
- why
-
September 28, 2019
Dr.
Conleth Murphy, an oncologist at Bon Secours Cork Cancer Center in
Ireland, discusses his research on scalp cooling in people being treated
with chemotherapy for cancer.Running time: 2:58
-
Immunotherapy to Treat Metastatic HER2-Positive Breast Cancer: ESMO 2019 Coverage
September 29, 2019
Dr.
Leisha Emens is professor of medicine in hematology/oncology at the
University of Pittsburgh Hillman Cancer Center. She is also co-leader of
the Hillman Cancer Immunology and Immunotherapy Program and director of
translational immunotherapy for the Women's Cancer Research Center. She
is internationally recognized for her work in breast cancer
immunotherapy.At the European Society for Medical Oncology 2019
Congress, she presented overall survival results from the KATE2 study,
which compared using the combination of Tecentriq, also called
atezolizumab, and Kadcyla, also called T-DM1, to Kadcyla alone to treat
HER2-positive metastatic breast cancer that had grown while being
treated with Herceptin and chemotherapy.Listen to the podcast to hear Dr. Emens discuss:
- the design of the KATE2 study
- why the study is encouraging, even though it didn't meet its primary endpoint
- what the results mean for people diagnosed with HER2-positive metastatic breast cancer
- her advice to people diagnosed with breast cancer who are interested in immunotherapy
Running time: 10:04
-
September 29, 2019
Dr.
Peter Schmid is chair in cancer medicine at Barts Cancer Institute,
Queen Mary University London and also serves as clinical director of the
Breast Cancer Centre at the St. Bartholomew Cancer Centre and honorary
consultant medical oncologist at Barts Hospital. His research focuses on
breast cancer, cancer immune therapy, and early drug development.At
the European Society for Medical Oncology 2019 Congress, he presented
results from the KEYNOTE-522 study showing that the combination of the
immunotherapy Keytruda (chemical name: pembrolizumab) and chemotherapy
before surgery to remove early-stage triple-negative breast cancer led
to a better pathologic complete response than chemotherapy alone. This
is the first phase III study using immunotherapy to treat early-stage
breast cancer.Listen to the podcast to hear Dr. Schmid discuss:
- the design of the KEYNOTE-522 study
- side effects related to both chemotherapy and Keytruda
- what these results mean for patients
Running time: 9:27
-
September 29, 2019
Dr.
Dennis Slamon is professor of medicine and executive vice chair for
research for the UCLA Department of Medicine. He also serves as director
of clinical/translational research and director of the Revlon/UCLA
Women's Cancer Research Program at the Jonsson Comprehensive Cancer
Center at UCLA. He is probably best known for doing the laboratory and
clinical research that led to the development of Herceptin, the first
medicine to specifically treat HER2-positive breast cancer. Dr. Slamon
has won numerous awards for his research. Earlier this month, he
received the 2019 Lasker Award for clinical medical research for his
groundbreaking work on Herceptin.At the European Society for
Medical Oncology 2019 Congress, he presented overall survival results
from the MONALEESA-3 study, looking at using the CDK4/6 inhibitor
Kisqali (chemical name: ribociclib) plus the hormonal therapy Faslodex
(chemical name: fulvestrant) to treat advanced-stage,
hormone-receptor-positive, HER2-negative breast cancer in postmenopausal
women.Listen to the podcast to hear Dr. Slamon explain:
- the background of the MONALEESA-3 study
- how much adding Kisqali to Faslodex improved overall survival compared to Faslodex alone
- treatment side effects seen in the study
- what the results mean for people diagnosed with metastatic hormone-receptor-positive, HER2-negative breast cancer
Running time: 9:10
-
Breast Cancer Research Highlights -- Heard in the Halls: Voices From ESMO 2019
September 29, 2019
Anne White, president of Lilly Oncology, discusses some of the most talked about breast cancer research presented at ESMO 2019.
Running time: 10:40
-
September 29, 2019
Dr.
George Sledge is professor of medicine and head of the Oncology
Division at Stanford University. A former president of the American
Society of Clinical Oncology, he specializes in breast cancer research.
He has published extensively on the treatment of metastatic breast
cancer and has been honored with numerous awards for his work.At
the European Society for Medical Oncology 2019 Congress, he presented
overall survival results from the MONARCH 2 study, which used Verzenio
(chemical name: abemaciclib) and Faslodex (chemical name: fulvestrant)
to treat metastatic hormone-receptor-positive, HER2-negative breast
cancer that was previously treated with hormonal therapy and had stopped
responding. The women in the study were premenopausal, perimenopausal,
or postmenopausal.Listen to the podcast to hear Dr. Sledge explain:
- the background of the MONARCH 2 study
- how much overall survival was improved
- the side effects seen in the study
- what the results mean for people diagnosed with metastatic hormone-receptor-positive, HER2-negative breast cancer
Running time: 6:45
-
How to Ease Aromatase Inhibitor-Related Pain
October 4, 2019
Ashish Khanna, M.D., is a physical medicine and rehabilitation specialist at the Kessler Institute for Rehabilitation and part of the ReVital Cancer Rehabilitation Program. Dr. Khanna completed his residency in physical medicine and rehabilitation at the Kingsbrook Jewish Rehabilitation Institute in Brooklyn, NY, where he became interested in cancer rehabilitation early on. He completed his fellowship subspecialization in cancer rehabilitation at Medstar Georgetown University and the National Rehabilitation Hospital in Washington, DC. He specializes in the treatment of people who have pain or functional issues as a result of cancer or cancer treatments, including people who have been diagnosed with breast cancer. This includes pain, shoulder issues, fatigue, joint pain from aromatase inhibitors, and other issues. He has lectured at numerous international conferences, has published peer-reviewed research on a variety of related topics, and is the co-author of an upcoming book on cancer rehabilitation.
Listen to the podcast to hear Dr. Khanna discuss:
- what aromatase inhibitors are and how they treat hormone-receptor-positive breast cancer
- why and how aromatase inhibitors cause joint pain
- how exercise can reduce aromatase inhibitor-related joint pain
- other ways to ease this joint pain
Running time: 22:56
-
Characteristics of Early-Stage Breast Cancer That Make It More Likely to Come Back
October 25, 2019
Dr. Chirag Shah is a radiation oncologist and director of clinical research for the department of radiation oncology at the Cleveland Clinic. Dr. Shah received his bachelor's degree from Youngstown State University and his medical degree from Northeast Ohio Medical University. He completed his internship and residency at William Beaumont Hospital from 2007 to 2012 and joined the Cleveland Clinic Staff in 2015. Dr. Shah serves as a reviewer for various medical journals and is a member of various medical societies. His primary research interests are breast cancer, sarcoma, prostate cancer, lymphoma, and innovative radiation treatment schedules as well as lymphedema. He has participated in numerous clinical trials.
In this podcast, Dr. Shah talks about specific characteristics of early-stage breast cancer that make the cancer more likely to come back, which doctors call recurrence, as well as what can be done to lower that risk.
Listen to the podcast to hear Dr. Shah discuss:
- the difference between local/regional recurrence and metastatic/distant recurrence
- the characteristics of early-stage breast cancer that make the risk of recurrence higher
Running time: 15:28
Listen now or read the transcript. -
Sharing Knowledge: Pairing Experts With Patient Advocates
November 8, 2019
Christine Hodgdon was diagnosed with de novo metastatic breast cancer in April 2015 and became heavily involved in the metastatic community after attending a Metavivor advocacy event on Capitol Hill to push for more research funding for metastatic breast cancer.
Christine volunteers with a number of breast cancer organizations, including Living Beyond Breast Cancer, METAvivor, and the Tigerlily Foundation. She also has contributed articles and blogs to organizations to raise awareness of metastatic breast cancer and serves as a peer mentor for the Young Survival Coalition.
Before she was diagnosed, Christine loved to travel and was a Peace Corps volunteer in Guatemala from 2011-2013. When she returned, she worked as a conservation biologist to save habitat for endangered species. Now Christine is using her science background to create an open-access online forum thestormriders.org that provides the most recent and scientifically accurate information about breast cancer and its treatments, including metastatic breast cancer clinical trials and drugs and therapies in the pipeline. She also has created a pilot program, pairing oncology experts with new patient advocates at the San Antonio Breast Cancer Symposium, which is what we talk about during this podcast.
Listen to the podcast to hear Christine talk about:
- how the cancer diagnoses changed her
- how she keeps up with breast cancer research
- her pilot program to pair oncology experts and patient advocates at the San Antonio Breast Cancer Symposium
- what she wants people to know about metastatic breast cancer
Running time: 28:33
-
Chemo Brain Update: Cancer-Related Cognitive Decline
November 22, 2019
Erica Guardascione is a speech-language pathologist at the Kessler Institute for Rehabilitation in Saddle Brook, New Jersey. She's also a curriculum developer and faculty member at ReVital Cancer Rehabilitation.
After completing her undergraduate degree in speech-language pathology at Hofstra University, Erica went on to pursue graduate studies at Nova Southeastern University. She has practiced for more than a decade as a clinical specialist in the Cognitive Rehabilitation Program at Kessler. The program is designed to help people with brain injuries rebuild cognitive skills, restore physical and emotional strength, and maximize independence. Erica is a clinical lead in the program.
Erica has a deep interest in cancer-related cognitive problems and is considered an authority on attention, focus, and memory impairments and rehabilitation strategies. As a faculty member at ReVital Cancer Rehabilitation, she recently co-led a continuing education course for therapists and other clinicians called "Cancer-Related Cognitive Decline."
Listen to the podcast to hear Erica explain:
- why "cancer-related cognitive decline" is the most up-to-date term for chemo brain
- the factors that can contribute to cognitive decline after a cancer diagnosis
- some broad steps that people can take to help manage any thinking and memory problems they may be having
Running time: 22:40
-
World-Record Swim 1 Year After Treatment
December 6, 2019
In September 2019, marathon swimmer Sarah Thomas did something that had never been done before: she swam the English Channel four times, non-stop. And she did this a year after completing treatment for stage II breast cancer.
Sarah started swimming lessons at age one and was on a year-round swim team by age 10. She swam on her high school team and in College at the University of Connecticut where she studied political science and journalism. She took a break from swimming while earning a master's degree at the University of Denver, but joined a masters' swim team after graduating.
In August 2017, Sarah swam 104.6 miles in Lake Champlain, the first current-neutral open water swim of more than 100 miles and the world record for the longest unassisted open water swim.
In November 2017, while planning her English Channel swim, she was diagnosed with breast cancer at age 35.
Listen to the podcast to hear Sarah talk about:
- how she found the breast lump and what she did after that
- how she talked to her doctors about treatments while she was planning her English Channel swim
- what she thought about and how she ate during the 54-hour swim
- how breast cancer has changed her
Running time: 22:12
Listen now or read the transcript.
Photo credit: James Musslewhite
-
Mets, Sex, and Side Effects – Heard in the Halls: Voices From the 2019 SABCS
December 11, 2019
Dr. Kelly Shanahan, metastatic patient advocate, METAvivor board member, and former OB/GYN talks about the Mets, Sex, and Side Effects panel that she comoderated at the 2019 San Antonio Breast Cancer Symposium. The panel was cosponsored by Breastcancer.org and Sermonix Pharmaceuticals.
Running time: 3:40
Listen now. -
December 11, 2019
Dr. Stephanie Graff, director of the Breast Cancer Program at the Sarah Cannon Cancer Institute, talks about why sexual health is so important for people living with metastatic breast disease and offers tips for people who may be uncomfortable bringing up the topic with their oncologist.
Running time: 2:20
-
Beneath the Breast – Heard in the Halls: Voices From the 2019 SABCS
December 11, 2019
Barbara and Tim Bigelow discuss Barbara's metastatic breast cancer diagnosis and the side effects she experienced as one of the first people treated with immunotherapy for breast cancer. A board member of METAvivor, Barbara also explains the Beneath the Breast project, the latest initiative of the #ThisIsMBC campaign.
Running time: 16:36
-
SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?
December 11, 2019
Dr. Rashmi Murthy, assistant professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, discusses the results of the HER2CLIMB study that she presented at the 2019 San Antonio Breast Cancer Symposium showing that the experimental medicine tucatinib offers benefits to people diagnosed with HER2-positive metastatic breast cancer and may be a new standard of care.
Listen to the episode to hear Dr. Murthy explain:
- a summary of the study results
- why this study included people with brain metastases
- the side effects of tucatinib
- why she thinks the results are practice changing
Running time: 8:22
Listen now. -
December 12, 2019
Dr. Luca Gianni, president of the Fondazione Michelangelo in Milan, discusses the results of the NeoTRIP trial, which looked to see if adding the immunotherapy medicine Tecentriq (chemical name: atezolizumab) to chemotherapy before surgery for triple-negative breast cancer with a high risk of recurrence could improve the time women lived without the cancer coming back.
Running time: 7:17
-
GRASP: Empowering Patients With Knowledge – Heard in the Halls: Voices From the 2019 SABCS
December 12, 2019
Felicia Johnson, who is living with metastatic disease, and Sharon Rivera-Sanchez, who was diagnosed in 2015 with triple-negative breast cancer, talk about what they learned during the GRASP (Guiding Researchers & Advocates to Scientific Partnerships) program.
Running time: 7:52
Listen now. -
SABCS 2019: Arimidex for Breast Cancer Prevention: Benefits Last Nearly 6 Years After Treatment Ends
December 12, 2019
Dr. Jack Cuzick is director of the Wolfson Institute of Preventive Medicine and head of the Center for Cancer Prevention at the Queen Mary University of London, where he holds the title of John Snow Professor of Epidemiology.
He is internationally known for his research showing tamoxifen can be used to treat estrogen-receptor-positive breast cancer, as well as his work to help develop the Tyrer-Cuzick breast cancer risk evaluation tool, which helps women and their doctors estimate a woman's risk of developing breast cancer.
At the 2019 San Antonio Breast Cancer Symposium, he presented the latest results from the International Breast Cancer Intervention Study II Prevention Trial, looking at whether 5 years of Arimidex (chemical name: anastrozole) can reduce breast cancer risk in postmenopausal women who have higher-than-average risk of the disease but have not been diagnosed.
Listen to the podcast to hear Dr. Cuzick discuss:
- how much Arimidex reduced risk after about 11 years of follow up
- why Arimidex is better than tamoxifen at reducing risk in high-risk postmenopausal women
- the side effects seen in the study and why side effect rates were the same in women who took Arimidex and women who took a placebo
- why it's unlikely that Arimidex will be approved by the U.S. Food and Drug Administration for this use, but why doctors will be able to prescribe it off-label
Running time: 9:25
Listen now. -
SABCS 2019: MRI Finds Breast Cancers Earlier Than Mammography in Women With Strong Family History
December 13, 2019
Dr. Madeleine Tilanus-Linthorst is a member of the department of surgery at the Erasmus University Medical Center in the Netherlands. At the 2019 San Antonio Breast Cancer Symposium, she presented research comparing breast cancer screening with MRI versus mammography in women at high risk of the disease because of strong family history. The results found that MRI found cancers earlier, when they were smaller in size and could potentially change screening standards in the Netherlands and other European countries.
Listen to the podcast to hear Dr. Tilanus-Linthorst explain:
- differences in screening recommendations between the United States and the Netherlands
- why it's important to find cancers earlier
- the risk of more false-positives with MRI screening
Running time: 11:06
Listen now. -
Top News at 2019 SABCS – Heard in the Halls: Voices From the 2019 SABCS
December 13, 2019
Jack Goodpasture, senior director of medical affairs at Eli Lilly and Company, discusses some of the research presented at the 2019 San Antonio Breast Cancer Symposium that might be most applicable to people diagnosed with breast cancer.
Running time: 5:11
-
SABCS 2019: Five More Years of Femara Seems to Reduce Breast Cancer Recurrence Risk for Some Women
December 13, 2019
Dr. Terry Mamounas is medical director of the comprehensive breast program at Orlando Health UF Health Cancer Center and is considered one of the country's top cancer doctors.
At the 2019 San Antonio Breast Cancer Symposium, he presented the latest results from a study looking at whether an additional five years of Femara after five years of a combination of tamoxifen and an aromatase inhibitor or five years of only an aromatase inhibitor offers benefits to postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
Listen to the podcast to hear Dr. Mamounas discuss:
- the results showing additional Femara reduced the risk of distant recurrence – the breast cancer coming back in a part of the body away from the breast
- the amount of improvement in event-free survival
- side effects associated with taking Femara for another five years
- how he's talking to his patients about these latest results
Running time: 18:32
-
What My Patients Are Asking: What Is the Lung Inflammation Side Effect Caused by CDK4/6 Inhibitors?
December 20, 2019
Brian Wojciechowski, M.D., practices medical oncology in Delaware County, Pennsylvania at Riddle, Taylor, and Crozer hospitals and also serves as Breastcancer.org's medical adviser. A native of South Philadelphia, he trained at Temple University School of Medicine and Lankenau Medical Center. Dr. Wojciechowski is a sought-after speaker on the topics of medical ethics and the biology of cancer.
In September 2019, the U.S. Food and Drug Administration released a statement warning that the CDK4/6 inhibitors used to treat breast cancer:
- Ibrance (chemical name: palbociclib)
- Kisqali (chemical name: ribociclib)
- Verzenio (chemical name: abemaciclib)
may cause rare but serious inflammation in the lungs.
Listen to the podcast to hear Dr. Wojciechowski talk about:
- how CDK4/6 inhibitors are used to treat breast cancer
- why we're just hearing about this side effect now
- he recommendations for anyone being treated with a CDK4/6 inhibitor
Running time: 7:11
-
Medical Records: Privacy and Access Rights Granted by HIPAA
January 3, 2020
Deven McGraw is the chief regulatory officer for Ciitizen, a tech company creating a platform that helps people collect, organize, and share their medical records digitally. Before joining Ciitizen, she directed U.S. health privacy and security policy as deputy director for health information privacy at the Department of Health and Human Services Office for Civil Rights, the office that oversees HIPAA policy and enforcement. She also served as acting chief privacy officer for the Office of the National Coordinator for Health IT. McGraw also served as an adviser to the Patient-Centered Outcomes Research Network, as well as the All of Us Research Initiative.
Listen to the podcast to hear Deven discuss:
- what HIPAA is and what it was created to do
- how HIPAA guarantees people access to their health information
- tips for requesting and then keeping track of your medical records
Running time: 22:39
-
Yoga: Benefits and Precautions for People With Breast Cancer
January 17, 2020
Vicki Flannery wears a number of hats: She's a nurse in the Kansas City area; she's a yoga instructor at weBuild4Life, a nonprofit that focuses on functional fitness and nutritional programs for cancer survivors and people with chronic illnesses; and she is a breast cancer survivor.
Vicki's yoga classes center around recovery, flexibility, and strengthening.
Listen to the podcast to hear Vicki talk about:
- what yoga is and examples of different types of yoga
- the benefits yoga can offer to people who've been diagnosed with breast cancer
- precautions people who've been diagnosed with breast cancer may want to consider
- how she modified her own yoga practice after being diagnosed with breast cancer
Running time: 29:58
-
Breast Cancer Inspired Me to Start a Lingerie Company
February 7, 2020
Dana Donofree is a designer and founder of AnaOno. After being diagnosed with stage I estrogen-receptor-positive, HER2-positive breast cancer almost 10 years ago at the age of 27, Dana began to design her first pieces to meet her need for sexy, beautiful lingerie during a recovery period that she calls "anything but sexy and beautiful."
She has made it her mission to design lingerie specifically for women who have had breast surgery, breast reconstruction, or are living with other conditions that cause pain because she believes that they shouldn't have to compromise between comfort and beauty.
On February 9, for the fourth year in a row, AnaOno is partnering with #Cancerland to put on a fashion show during New York Fashion Week to raise funds for METAvivor. All the models in the show are women who have been touched in some way by breast cancer or its risk — from previvors to people with early-stage disease to people with stage IV disease — to start new conversations between all these groups.
Listen to the podcast to hear Dana talk about:
- her diagnosis and treatment and how it inspired her to start AnaOno
- where the AnaOno name came from
- The show during Fashion Week and what she hopes to accomplish with it
- her tips for someone who has just been diagnosed with breast cancer
Running time: 29:32
-
Support Services for Caregivers
February 21, 2020
Mallori Thompson is manager of the Duke Cancer Patient Support Program at the Duke Cancer Institute. Mallori received her master's degree in mental health counseling from North Carolina Central University. Her area of expertise is the psychosocial care of patients diagnosed with cancer and their families. Her research involves learning about how cancer affects people who've been diagnosed, as well as their family members and their relationships. Mallori leads a multidisciplinary team of clinicians and researchers, including medical family therapists, oncology recreation therapists, child life specialists, and psychologists, as well as people who coordinate volunteer services and self-image programs.
Listen to the podcast to hear Mallori explain:
- how the needs and concerns of cancer caregivers are different from those of people diagnosed with cancer
- the services that caregivers seem to use the most
- her top three suggestions for a caregiver who's feeling overwhelmed or burned out
Running time: 15:48
-
Managing Shoulder Issues After Breast Cancer Treatment
March 6, 2020
Ashish Khanna, M.D., is a physical medicine and rehabilitation specialist at the Kessler Institute for Rehabilitation and part of the ReVital Cancer Rehabilitation Program. Dr. Khanna completed his residency in physical medicine and rehabilitation at the Kingsbrook Jewish Rehabilitation Institute in Brooklyn, NY, where he became interested in cancer rehabilitation early on. He completed his fellowship subspecialization in cancer rehabilitation at Medstar Georgetown University/National Rehabilitation Hospital in Washington, DC. He specializes in the treatment of people who have pain or functional issues as a result of cancer or cancer treatments, including people who have been diagnosed with breast cancer. This includes pain, shoulder issues, fatigue, joint pain from aromatase inhibitors, and other issues. He has lectured at numerous international conferences, has published peer-reviewed research on a variety of related topics, and is the co-author of an upcoming book on cancer rehabilitation.
Listen to the podcast to hear Dr. Khanna talk about:
- the shoulder problems that can happen as a result of breast cancer treatment
- links between lymphedema and shoulder problems
- how shoulder problems can be managed
- his top three tips for people who are having shoulder issues
Running time: 34:05
-
COVID-19: What We Know Now
March 18, 2020
Dr. Angela Rasmussen is an associate research scientist in the Center for Infection and Immunity at Columbia University Mailman School of Public Health. Her research focuses on how hosts respond to infection by viruses in order to determine the severity of the infection and outcomes of the disease, as well as to look for new pathways to treat the disease and how to design vaccines. She is especially interested in newly emerging viruses, such as COVID-19.
Listen to the podcast to hear her explain:
- where COVID-19 testing stands right now and what needs to happen to improve testing
- some measures that people who are undergoing chemotherapy or other immunosuppressing treatments might take to protect themselves
- how handwashing removes the COVID-19 virus membrane
- some of the myths surrounding COVID-19 and why they're untrue
Running time: 30:34
-
Managing Loneliness and Anxiety During This Time of Social Distancing
March 19, 2020
Kelly Grosklags is an experienced therapist who dedicated her practice to minimizing suffering through her work in oncology, palliative care, and hospice. Kelly is a licensed clinical social worker, a board-certified diplomate in clinical social work, and a fellow of the American Academy of Grief Counseling. Kelly now teaches and speaks frequently about end-of-life issues, including care, grief and loss, both in person, on her website, Conversations With Kelly, and on her Conversations With Kelly Facebook page. Her support has helped patients, caregivers, and health professionals cope with depression and anxiety and transform fear into hope.
Listen to the podcast to hear Kelly discuss ways to combat the loneliness and anxiety people may be feeling during this time of isolation and social distancing because of COVID-19, including:
- how to stay emotionally close while being physically distant
- how breathing and living in the now can help ease anxiety
- why taking up a new hobby can be good for your psyche
Running time: 47:15
Categories
- All Categories
- 679 Advocacy and Fund-Raising
- 289 Advocacy
- 68 I've Donated to Breastcancer.org in honor of....
- Test
- 322 Walks, Runs and Fundraising Events for Breastcancer.org
- 5.6K Community Connections
- 282 Middle Age 40-60(ish) Years Old With Breast Cancer
- 53 Australians and New Zealanders Affected by Breast Cancer
- 208 Black Women or Men With Breast Cancer
- 684 Canadians Affected by Breast Cancer
- 1.5K Caring for Someone with Breast cancer
- 455 Caring for Someone with Stage IV or Mets
- 260 High Risk of Recurrence or Second Breast Cancer
- 22 International, Non-English Speakers With Breast Cancer
- 16 Latinas/Hispanics With Breast Cancer
- 189 LGBTQA+ With Breast Cancer
- 152 May Their Memory Live On
- 85 Member Matchup & Virtual Support Meetups
- 375 Members by Location
- 291 Older Than 60 Years Old With Breast Cancer
- 177 Singles With Breast Cancer
- 869 Young With Breast Cancer
- 50.4K Connecting With Others Who Have a Similar Diagnosis
- 204 Breast Cancer with Another Diagnosis or Comorbidity
- 4K DCIS (Ductal Carcinoma In Situ)
- 79 DCIS plus HER2-positive Microinvasion
- 529 Genetic Testing
- 2.2K HER2+ (Positive) Breast Cancer
- 1.5K IBC (Inflammatory Breast Cancer)
- 3.4K IDC (Invasive Ductal Carcinoma)
- 1.5K ILC (Invasive Lobular Carcinoma)
- 999 Just Diagnosed With a Recurrence or Metastasis
- 652 LCIS (Lobular Carcinoma In Situ)
- 193 Less Common Types of Breast Cancer
- 252 Male Breast Cancer
- 86 Mixed Type Breast Cancer
- 3.1K Not Diagnosed With a Recurrence or Metastases but Concerned
- 189 Palliative Therapy/Hospice Care
- 488 Second or Third Breast Cancer
- 1.2K Stage I Breast Cancer
- 313 Stage II Breast Cancer
- 3.8K Stage III Breast Cancer
- 2.5K Triple-Negative Breast Cancer
- 13.1K Day-to-Day Matters
- 132 All things COVID-19 or coronavirus
- 87 BCO Free-Cycle: Give or Trade Items Related to Breast Cancer
- 5.9K Clinical Trials, Research News, Podcasts, and Study Results
- 86 Coping with Holidays, Special Days and Anniversaries
- 828 Employment, Insurance, and Other Financial Issues
- 101 Family and Family Planning Matters
- Family Issues for Those Who Have Breast Cancer
- 26 Furry friends
- 1.8K Humor and Games
- 1.6K Mental Health: Because Cancer Doesn't Just Affect Your Breasts
- 706 Recipe Swap for Healthy Living
- 704 Recommend Your Resources
- 171 Sex & Relationship Matters
- 9 The Political Corner
- 874 Working on Your Fitness
- 4.5K Moving On & Finding Inspiration After Breast Cancer
- 394 Bonded by Breast Cancer
- 3.1K Life After Breast Cancer
- 806 Prayers and Spiritual Support
- 285 Who or What Inspires You?
- 28.7K Not Diagnosed But Concerned
- 1K Benign Breast Conditions
- 2.3K High Risk for Breast Cancer
- 18K Not Diagnosed But Worried
- 7.4K Waiting for Test Results
- 603 Site News and Announcements
- 560 Comments, Suggestions, Feature Requests
- 39 Mod Announcements, Breastcancer.org News, Blog Entries, Podcasts
- 4 Survey, Interview and Participant Requests: Need your Help!
- 61.9K Tests, Treatments & Side Effects
- 586 Alternative Medicine
- 255 Bone Health and Bone Loss
- 11.4K Breast Reconstruction
- 7.9K Chemotherapy - Before, During, and After
- 2.7K Complementary and Holistic Medicine and Treatment
- 775 Diagnosed and Waiting for Test Results
- 7.8K Hormonal Therapy - Before, During, and After
- 50 Immunotherapy - Before, During, and After
- 7.4K Just Diagnosed
- 1.4K Living Without Reconstruction After a Mastectomy
- 5.2K Lymphedema
- 3.6K Managing Side Effects of Breast Cancer and Its Treatment
- 591 Pain
- 3.9K Radiation Therapy - Before, During, and After
- 8.4K Surgery - Before, During, and After
- 109 Welcome to Breastcancer.org
- 98 Acknowledging and honoring our Community
- 11 Info & Resources for New Patients & Members From the Team